Mutant, Apoptosis, Tumor suppressor gene, Cancer research and Cell culture are her primary areas of study. Her work in Mutant covers topics such as Mutation which are related to areas like Cell biology and DNA. Her Cell biology research is multidisciplinary, incorporating elements of Genetics and Gene expression.
Her biological study spans a wide range of topics, including In vitro, Transfection and In vivo. Her Tumor suppressor gene research incorporates themes from Retinoblastoma, Binding site and Point mutation. Her research in Cancer research intersects with topics in Immunoprecipitation, Lymphoblast, Downregulation and upregulation, Proto-Oncogene Proteins c-mdm2 and Cell cycle.
Her main research concerns Cancer research, Apoptosis, Mutant, Cell biology and Cancer. Her studies in Cancer research integrate themes in fields like Cancer cell, Downregulation and upregulation, Mdm2, Signal transduction and Tumor suppressor gene. Her Apoptosis research incorporates elements of Immunology, Cell culture, In vitro and DNA damage.
The concepts of her Mutant study are interwoven with issues in Mutation, Molecular biology, In vivo and Function. Her studies deal with areas such as Gene expression, Suppressor, DNA, Cancer therapy and Regulation of gene expression as well as Cell biology. Her Cancer research includes themes of NKG2D, Innate immune system, Immune system and Photodynamic therapy.
Galina Selivanova spends much of her time researching Cancer research, Cell biology, Gene, Apoptosis and Mdm2. The various areas that Galina Selivanova examines in her Cancer research study include Cancer cell, Wild type and DNA repair. Her study in Apoptosis is interdisciplinary in nature, drawing from both Cell and DNA damage.
Galina Selivanova combines subjects such as Suppressor, Cancer, Function and Mechanism of action with her study of Mdm2. Her work in Tumor suppressor gene tackles topics such as Cell culture which are related to areas like Molecular biology. She focuses mostly in the field of In vivo, narrowing it down to topics relating to Mutant and, in certain cases, Clinical trial and Pharmacology.
Her primary scientific interests are in Mdm2, MDMX, Cancer research, Cancer and Programmed cell death. Her Mdm2 research focuses on Function and how it connects with Gene. Her study looks at the relationship between Cancer research and fields such as DNA repair, as well as how they intersect with chemical problems.
Her Programmed cell death study incorporates themes from Oxidative stress and Cell biology. Her Cell biology research is multidisciplinary, incorporating perspectives in Cancer cell, Apoptosis, DNA damage and Synthetic lethality. Her Suppressor study combines topics in areas such as Clinical trial, Mutant, Immune system, Small molecule and Pharmacology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Vladimir J.N. Bykov;Natalia Issaeva;Alexandre Shilov;Monica Hultcrantz.
Nature Medicine (2002)
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.
Natalia Issaeva;Przemyslaw Bozko;Martin Enge;Marina Protopopova.
Nature Medicine (2004)
Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain.
Galina Selivanova;Violetta Iotsova;Violetta Iotsova;Ismail Okan;Michael Fritsche.
Nature Medicine (1997)
EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins
Laszlo Szekely;Galina Selivanova;Kristinn P. Magnusson;George Klein.
Proceedings of the National Academy of Sciences of the United States of America (1993)
Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction.
Mariam Grigorian;Susanne Andresen;Eugene Tulchinsky;Marina Kriajevska.
Journal of Biological Chemistry (2001)
p53 binds single stranded DNA ends and catalyzes DNA renaturation and strand transfer
G Bakalkin;T Yakovleva;G Selivanova;K P Magnusson.
Proceedings of the National Academy of Sciences of the United States of America (1994)
Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells
Dawei Xu;Qian Wang;Astrid Gruber;Magnus Björkholm.
Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs
Vladimir J. N. Bykov;Natalia Issaeva;Nicole Zache;Alexandre Shilov.
Journal of Biological Chemistry (2005)
p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain
Georgy Bakalkin;Galina Selivanova;Tatjana Yakovleva;Elena Kiseleva.
Nucleic Acids Research (1995)
Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
G Selivanova;K G Wiman.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: